VA
REGN icon

Verdad Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Verdad Advisers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$219K Buy
+283
New +$217K 0.25% 126
2024
Q3 		$676K Sell
643
-697
-52% -$776K 0.9% 39
2024
Q2 		$1.41M Buy
1,340
+81
+6% +$78.5K 1.63% 12
2024
Q1 		$1.21M Buy
+1,259
New +$1.2M 1.32% 14

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Verdad Advisers's REGN Position: Q1 2026 in Review

Verdad Advisers opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 283 shares worth $219K. The stake represents 0.25% of the portfolio and ranks #126 among its holdings. This is a return to the name: Verdad Advisers previously reported a position in REGN as recently as Q3 2024.

Verdad Advisers first reported a position in REGN in Q1 2024 and has held it in 4 quarters since. The position peaked at $1.41M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Verdad Advisers held 283 shares of Regeneron Pharmaceuticals worth $219K as of Q1 2026.
  • Regeneron Pharmaceuticals was a new Verdad Advisers position in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.25% of Verdad Advisers's portfolio in Q1 2026, its #126 holding.
  • Verdad Advisers first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 4 quarters since.
  • Verdad Advisers's Regeneron Pharmaceuticals position peaked at $1.41M in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.